本次会议是否有被否决议案：无 一、 会议召开和出席情况 证券代码：688299 证券简称：长阳科技 公告编号：2026-009 宁波长阳科技股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （一） 股东会召开的时间：2026 年 2 月 25 日 （二） 股东会召开的地点：宁波市江北区庆丰路 999 号公司一楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 168 | | --- | --- | | 普通股股东人数 | 168 | | 2、出席会议的股东所持有的表决权数量 | 57,496,821 | | 普通股股东所持有表决权数量 | 57,496,821 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 20.3679 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 20.3679 | （四） 表决方式 ...

国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 Grandall Law Firm (Shanghai) 中国 上海 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼，200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China, 200085 致：宁波长阳科技股份有限公司 国浩律师（上海）事务所（以下简称"本所"）接受宁波长阳科技股份有限 公司（以下简称"公司"）委托，指派本所律师出席公司 2026 年第一次临时股 东会（以下简称"本次股东会"）。本所律师根据《中华人民共和国证券法》（以 下简称"《证券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规、部门 规章和规舃性文件以及《宁波长阳科技股份有限公司章程》（以下简称"《公司 章程》"）的规定，就公司本次股东会的召集与召开程序、出席会议人员资格、 召集人资格、会议表决程序和表决结果的合法性等有关法律问题出具法律意见书。 对本法律意见书的出具，本所律 ...

复星医药公告称，其控股子公司复宏汉霖在斯鲁利单抗注射液海外许可方面有新进展。2月24日，复宏 汉霖与KGbio签订《修订及部分终止协议》，终止《2023年独家许可协议》及印尼以外区域的相关许 可，复宏汉霖将依转让进展向KGbio支付至多3375万美元里程碑付款。同日，复宏汉霖与Abbott签订 《2024年许可协议之修正案》，扩展许可区域，Abbott将依条件额外支付至多4600万美元监管里程碑 款、至多8000万美元销售里程碑款。此次进展旨在拓展海外市场，但与Abbott合作及相关款项收取存在 不确定性。 ...

Core Viewpoint - Recently, Fosun Pharma announced that its subsidiary, Fuhong Hanlin, received approval from the National Medical Products Administration to conduct Phase I clinical trials for HLX15-SC, a recombinant anti-CD38 fully human monoclonal antibody injection for the treatment of multiple myeloma [1] Group 1: Clinical Development - Fuhong Hanlin plans to conduct relevant clinical research for HLX15 in China once conditions are met [1] - HLX15 is a biosimilar to Daratumumab, with both subcutaneous (HLX15-SC) and intravenous (HLX15-IV) formulations intended for the treatment of multiple myeloma [1] Group 2: Financial Investment - As of January 2026, the company's cumulative R&D investment is approximately 192 million yuan [1] - According to the latest data, the global sales of Daratumumab formulations are expected to reach approximately 12.882 billion USD in 2024 [1]

公司将于2026年2月25日召开临时股东会，审议上述终止项目和担保议案，会议采取现场与网络投票结 合方式。此外，公司决定将首次公开发行募投项目节余资金约2280.65万元永久补充流动资金，以优化 账户管理。 业绩经营情况 以上内容基于公开资料整理，不构成投资建议。 长阳科技预计2025年归属净利润亏损1.16亿元至1.68亿元，主要因产品市场竞争加剧及计提资产减值损 失所致。 经济观察网 长阳科技拟终止"年产3,000万平方米高端光学深加工薄膜项目"，原因为市场竞争激烈及投 资回报不佳，该事项已获董事会通过，尚需股东会批准。公司计划为全资子公司2026年度银行综合授信 提供不超过10亿元人民币担保，担保事项已通过董事会审议，待股东会决议。 公司状况 ...

Group 1 - The core viewpoint of the article is that Changyang Technology (688299.SH) has stated there are currently no plans for mergers and acquisitions [1]

Core Viewpoint - Changyang Technology (688299.SH) is accelerating the development and validation of its CPI film project, which involves transparent polyimide films [1] Group 1: Project Development - The company is currently constructing its CPI project and aims to expedite the development and validation of CPI films [1] - The solid or semi-solid battery electrolyte composite membrane, known as the skeleton membrane, has received orders from leading domestic and international clients [1] Group 2: Market Demand and Financial Impact - The market demand for the skeleton membrane product has not yet ramped up, resulting in a small revenue amount [1] - The short-term financial impact on the company's operating performance is expected to be minimal [1] Group 3: Ongoing Developments - The ion-conducting membrane that the company is developing is still in the validation phase [1]

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: Investment Strategy - Companies are now trading based more on actual execution capabilities rather than solely on licensing deal expectations [1] - Achieving returns that exceed the industry average this year will rely more on key data releases, actual transactions, and visibility on profit realization or turning points [1] Group 2: Sector Analysis - The outlook for CDMO companies is becoming more constructive due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - The ratings for WuXi AppTec and WuXi AppTec Holdings have been upgraded to "Buy" [1] Group 3: Selective Strategy in Biotech and Pharma - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing some promise, along with actual transaction expectations [1] - Companies such as Kelun-Biotech, Innovent Biologics, and Hansoh Pharmaceutical are viewed positively [1] Group 4: Medical Devices Sector - The medical devices sector maintains a neutral outlook, as the industry has bottomed out but requires time for gradual recovery [1] - Recommendations include buying Angelalign Technology and Weigao Group [1]

宁波长阳科技股份有限公司 2026 年第一次临时股东会会议资料 证券代码：688299 证券简称：长阳科技 宁波长阳科技股份有限公司 2026 年第一次临时股东会会议资料 2026 年 2 月 宁波长阳科技股份有限公司 2026 年第一次临时股东会会议资料 宁波长阳科技股份有限公司 2026 年第一次临时股东会会议资料目录 | 宁波长阳科技股份有限公司 年第一次临时股东会会议须知 2026 | 1 | | --- | --- | | 宁波长阳科技股份有限公司 2026 年第一次临时股东会会议议程 | 3 | | 议案一：关于终止超募资金投资项目的议案 | 5 | | 议案二：关于为全资子公司向银行申请综合授信额度提供担保的议案 | 12 | 宁波长阳科技股份有限公司 2026 年第一次临时股东会会议资料 宁波长阳科技股份有限公司 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证大 会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司股东会规则》以及《宁波长阳科技股份有限公司章程》、《宁波长阳科技股份 有限公司股东会议事规则》等相关 ...

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Changyang Technology, including stock price movements and trading volumes [1][2] - On February 2, Changyang Technology's stock fell by 5.31%, with a trading volume of 280 million yuan. The net financing purchase on that day was 29.83 million yuan, indicating strong investor interest despite the price drop [1] - As of February 2, the total margin balance for Changyang Technology was 448 million yuan, accounting for 7.95% of its market capitalization, which is above the 60th percentile of the past year [1] Group 2 - As of September 30, the number of shareholders for Changyang Technology increased by 50.56% to 22,600, while the average circulating shares per person decreased by 33.58% to 12,718 shares [2] - For the period from January to September 2025, Changyang Technology reported a revenue of 809 million yuan, a year-on-year decrease of 19.38%, and a net profit attributable to shareholders of -5.34 million yuan, a significant decline of 128.82% [2] - Since its A-share listing, Changyang Technology has distributed a total of 130 million yuan in dividends, with 28.32 million yuan distributed over the past three years [3]